Interim study on state agency effectiveness to monitor and act on inappropriate prescribing of prescription drugs and controlled substances

2025 Regular Session

Proposes an interim legislative study to evaluate how state agencies monitor and act on inappropriate prescribing of prescription drugs and controlled substances.

(LC) Draft Died in Process

#alcoholanddrugs #healthcareservices(seealso:health) #legislature #interimstudies

LC 4477 — Interim study on state agency effectiveness to monitor and act on inappropriate prescribing of prescription drugs and controlled substances

Overview

LC 4477 is a draft bill introduced on March 26, 2025, intended to authorize an interim study by the legislature to evaluate how state agencies monitor and respond to inappropriate prescribing of prescription drugs and controlled substances. The bill is categorized as a legislative draft (LC) and, as of the latest actions, its status is “Draft Died in Process,” with the draft published on May 27, 2025.

Purpose and Intent

The primary aim, as reflected in the title, is to assess the effectiveness of state agencies in monitoring prescribing practices and in taking action against inappropriate prescribing of prescription medications and controlled substances.

The bill seeks to identify gaps, inefficiencies, and opportunities for improvement in oversight, data collection, enforcement, and coordination among relevant agencies.

Key Provisions (Notes)

Specific statutory language, scope, and mechanisms are not provided in the information available. The bill, by its title, would ordinarily be expected to:

Establish or authorize an interim study conducted by the Legislature.
Define the study’s scope (which agencies and data systems are examined) and the questions to be answered.
Designate a process for investigators or a study committee, including timelines, methods, and stakeholder engagement.
Require a final report to be delivered to the Legislature with findings and recommendations.

Given the draft status, the exact provisions (membership, funding, data access, reporting formats) are not specified in the provided summary.

Affected Parties

Directly affected: state agencies responsible for health care and drug oversight, such as departments or boards involved in prescription monitoring and enforcement (though specific agencies are not named in the provided summary).

Indirectly affected: health care providers, pharmacists, patients, and the public, through potential subsequent policy changes or improved oversight.

Timeline and Status

Introduced: March 26, 2025.

Legislative action: Draft Died in Process on May 27, 2025.

Status implication: The bill did not advance in its current form; if revived, it would need new action in the legislature.

Potential Impact (If Enacted)

A successful interim study could yield recommendations to enhance monitoring, data sharing, and enforcement related to inappropriate prescribing.

Outcomes might include proposed statutory or administrative reforms, improved inter-agency coordination, and clearer reporting to the Legislature.

Summary

LC 4477 proposes an interim legislative study to evaluate state agency effectiveness in monitoring and acting on inappropriate prescribing of prescription drugs and controlled substances. With its draft status and eventual death in process, the bill did not become law in its current form, but its stated objective centers on improving oversight and accountability in prescription practices.